• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·VASO
Share

Vaso Corporation Stocks

$ 0.29Last Updated 07.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 52.80M

$ 0.29
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions: 1. IT (Information Technology): This segment is dedicated to providing specialized IT solutions for the healthcare sector, alongside managed network technology services. Its services encompass managed diagnostic imaging applications, network infrastructure management, network transport, and comprehensive cybersecurity solutions. 2. Professional Sales Service: This division primarily focuses on the distribution of capital medical equipment manufactured by General Electric Healthcare (GEHC) to mid-sized healthcare providers. Its offerings include GEHC diagnostic imaging hardware, associated service contracts, training programs, and financial services facilitated by both GEHC and external partners. 3. Equipment: This segment concentrates on the development, manufacturing, sales, and servicing of its own proprietary medical devices. Its product portfolio features the Biox series, which includes Holter monitors and ambulatory blood pressure recorders; the ARCS series software for analyzing, reporting, and communicating ECG and blood pressure data; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation (EECP) therapy systems, used for non-invasive, outpatient treatment of ischemic heart disease. Founded in 1987, the company was originally named Vasomedical, Inc. before officially rebranding as Vaso Corporation in November 2016. Vaso Corporation maintains its corporate headquarters in Plainview, New York.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expensive' on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.10.2026 05:11

Lukoil's overseas assets are once again up for sale: the deal with Carlyle fell through

09.10.2026 03:50

Blue Origin funding round makes Bezos world’s second-richest person

09.10.2026 02:09

SpaceX Takes on AT&T and Verizon: Starlink Could Become a Major Cell Phone Carrier

09.10.2026 01:06

OpenAI revenue disappointment hits AI stocks, sending Nasdaq 100 down more than 1%

08.10.2026 23:47

OpenAI's revenue fell $20 billion short of expectations. Tech stocks fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026